Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.72 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.72 |
| ▸ | HTR3B | O95264 | 6/20 | 0.72 |
| ▸ | HTR3A | P46098 | 6/20 | 0.72 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.72 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9646131 | 0.99 | CHRNA7 (0.70) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9732560 | 0.90 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2820045 | 0.86 | CHRM3 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2821688 | 0.86 | CHRM3 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2819761 | 0.86 | CHRM3 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2819382 | 0.86 | CHRM3 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20476305 | 0.84 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7218899 | 0.84 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2229231 | 0.80 | CHRNA7 (0.67) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2229225 | 0.80 | CHRNA7 (0.67) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | claimed |
| EP-0327335-A1 | Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency | SYNTHELABO (FR) | 1989-08-09 | — | — | EP | claimed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | claimed |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9714242-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| US-9067931-B2 | 2-heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-05 | — | — | US | disclosed |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8884017-B2 | 2-heteroarylcarboxylic acid amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20100324085-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-12-23 | — | — | US | disclosed |
| US-7795453-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER HEALTH AG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | disclosed |
| EP-0327335-A1 | Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency | SYNTHELABO (FR) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | CHRNA7 354/4885HTR3E 785/4885HTR3B 650/4885 |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3E 278/4885HTR3B 141/4885 |
| US-20100324085-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3E 1133/4885HTR3B 608/4885 |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3E 1133/4885HTR3B 608/4885 |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3E 1133/4885HTR3B 608/4885 |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3E 1265/4885HTR3B 668/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | CHRNA7 2/4885HTR3E 650/4885HTR3B 273/4885 |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3E 278/4885HTR3B 141/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3E 278/4885HTR3B 141/4885 |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3E 1133/4885HTR3B 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.